

Tim Spelman

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2014252/publications.pdf>

Version: 2024-02-01

81
papers

3,288
citations

172457

29
h-index

161849

54
g-index

83
all docs

83
docs citations

83
times ranked

3424
citing authors

#	ARTICLE	IF	CITATIONS
1	Defining secondary progressive multiple sclerosis. <i>Brain</i> , 2016, 139, 2395-2405.	7.6	281
2	Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study. <i>Lancet Neurology</i> , The, 2020, 19, 307-316.	10.2	219
3	Associations of Disease-Modifying Therapies With COVID-19 Severity in Multiple Sclerosis. <i>Neurology</i> , 2021, 97, e1870-e1885.	1.1	168
4	Defining reliable disability outcomes in multiple sclerosis. <i>Brain</i> , 2015, 138, 3287-3298.	7.6	162
5	Predictors of long-term disability accrual in relapse-onset multiple sclerosis. <i>Annals of Neurology</i> , 2016, 80, 89-100.	5.3	158
6	Treatment decisions in multiple sclerosis – insights from real-world observational studies. <i>Nature Reviews Neurology</i> , 2017, 13, 105-118.	10.1	154
7	Switch to natalizumab versus fingolimod in active relapsing-remitting multiple sclerosis. <i>Annals of Neurology</i> , 2015, 77, 425-435.	5.3	143
8	Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study. <i>Lancet Neurology</i> , The, 2017, 16, 271-281.	10.2	134
9	Comparison of Switch to Fingolimod or Interferon Beta/Glatiramer Acetate in Active Multiple Sclerosis. <i>JAMA Neurology</i> , 2015, 72, 405.	9.0	100
10	Long-term safety and effectiveness of natalizumab treatment in clinical practice: 10 years of real-world data from the Tysabri Observational Program (TOP). <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 660-668.	1.9	97
11	Towards personalized therapy for multiple sclerosis: prediction of individual treatment response. <i>Brain</i> , 2017, 140, 2426-2443.	7.6	94
12	Clinical and virological predictors of hepatic flares in pregnant women with chronic hepatitis B. <i>Gut</i> , 2015, 64, 1810-1815.	12.1	92
13	Treatment Escalation vs Immediate Initiation of Highly Effective Treatment for Patients With Relapsing-Remitting Multiple Sclerosis. <i>JAMA Neurology</i> , 2021, 78, 1197.	9.0	90
14	Optimal Periprosthetic Tissue Specimen Number for Diagnosis of Prosthetic Joint Infection. <i>Journal of Clinical Microbiology</i> , 2017, 55, 234-243.	3.9	78
15	Discontinuing disease-modifying therapy in MS after a prolonged relapse-free period: a propensity score-matched study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, 1133-1137.	1.9	76
16	Development of a Prognostic Nomogram for Predicting the Probability of Nonresponse to Total Knee Arthroplasty 1 Year After Surgery. <i>Journal of Arthroplasty</i> , 2016, 31, 1654-1660.	3.1	73
17	Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 90, 458-468.	1.9	71
18	Seasonal variation of relapse rate in multiple sclerosis is latitude dependent. <i>Annals of Neurology</i> , 2014, 76, 880-890.	5.3	67

#	ARTICLE	IF	CITATIONS
19	Higher latitude is significantly associated with an earlier age of disease onset in multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, 1343-1349.	1.9	63
20	Effect of Disease-Modifying Therapy on Disability in Relapsing-Remitting Multiple Sclerosis Over 15 Years. <i>Neurology</i> , 2021, 96, e783-e797.	1.1	54
21	COVID-19 in people with multiple sclerosis: A global data sharing initiative. <i>Multiple Sclerosis Journal</i> , 2020, 26, 1157-1162.	3.0	50
22	Highly active immunomodulatory therapy ameliorates accumulation of disability in moderately advanced and advanced multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2017, 88, 196-203.	1.9	49
23	Comparative effectiveness of rituximab relative to IFN- β or glatiramer acetate in relapsing-remitting MS from the Swedish MS registry. <i>Multiple Sclerosis Journal</i> , 2018, 24, 1087-1095.	3.0	44
24	Predictors of disability worsening in clinically isolated syndrome. <i>Annals of Clinical and Translational Neurology</i> , 2015, 2, 479-491.	3.7	43
25	Cladribine versus fingolimod, natalizumab and interferon β for multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2018, 24, 1617-1626.	3.0	36
26	The effect of oral immunomodulatory therapy on treatment uptake and persistence in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2016, 22, 520-532.	3.0	34
27	Prognostic indicators in pediatric clinically isolated syndrome. <i>Annals of Neurology</i> , 2017, 81, 729-739.	5.3	34
28	The effect of antiretroviral intensification with dolutegravir on residual virus replication in HIV-infected individuals: a randomised, placebo-controlled, double-blind trial. <i>Lancet HIV</i> , 2018, 5, e221-e230.	4.7	34
29	Impact of Anti-PD-1 and Anti-CTLA-4 on the Human Immunodeficiency Virus (HIV) Reservoir in People Living With HIV With Cancer on Antiretroviral Therapy: The AIDS Malignancy Consortium 095 Study. <i>Clinical Infectious Diseases</i> , 2021, 73, e1973-e1981.	5.8	34
30	Comparative efficacy of first-line natalizumab vs IFN- β or glatiramer acetate in relapsing MS. <i>Neurology: Clinical Practice</i> , 2016, 6, 102-115.	1.6	33
31	Early treatment delays long-term disability accrual in RRMS: Results from the BMSD network. <i>Multiple Sclerosis Journal</i> , 2021, 27, 1543-1555.	3.0	33
32	Contribution of different relapse phenotypes to disability in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2017, 23, 266-276.	3.0	30
33	Increased rate of hospitalisation for COVID-19 among rituximab-treated multiple sclerosis patients: A study of the Swedish multiple sclerosis registry. <i>Multiple Sclerosis Journal</i> , 2022, 28, 1051-1059.	3.0	29
34	The Surgeon's Role in the Opioid Crisis: A Narrative Review and Call to Action. <i>Frontiers in Surgery</i> , 2020, 7, 4.	1.4	23
35	Lymphocyte count in peripheral blood is not associated with the level of clinical response to treatment with fingolimod. <i>Multiple Sclerosis and Related Disorders</i> , 2018, 19, 105-108.	2.0	22
36	Predictors of relapse and disability progression in MS patients who discontinue disease-modifying therapy. <i>Journal of the Neurological Sciences</i> , 2018, 391, 72-76.	0.6	22

#	ARTICLE	IF	CITATIONS
37	Gaps in the HIV diagnosis and care cascade for migrants in Australia, 2013–2017: A cross-sectional study. <i>PLoS Medicine</i> , 2020, 17, e1003044.	8.4	22
38	Multiple sclerosis risk variants regulate gene expression in innate and adaptive immune cells. <i>Life Science Alliance</i> , 2020, 3, e202000650.	2.8	22
39	The effect of mindfulness training prior to total joint arthroplasty on post-operative pain and physical function: A randomised controlled trial. <i>Complementary Therapies in Medicine</i> , 2019, 46, 195-201.	2.7	19
40	Medication Chart Intervention Improves Inpatient Thromboembolism Prophylaxis. <i>Chest</i> , 2012, 141, 632-641.	0.8	18
41	Quantifying risk of early relapse in patients with first demyelinating events: Prediction in clinical practice. <i>Multiple Sclerosis Journal</i> , 2017, 23, 1346-1357.	3.0	18
42	Pregnancy Outcomes in Men and Women Treated With Teriflunomide. A Population-Based Nationwide Danish Register Study. <i>Frontiers in Immunology</i> , 2018, 9, 2706.	4.8	18
43	Natalizumab treatment shows low cumulative probabilities of confirmed disability worsening to EDSS milestones in the long-term setting. <i>Multiple Sclerosis and Related Disorders</i> , 2018, 24, 11-19.	2.0	17
44	Treatment Switching and Discontinuation Over 20 Years in the Big Multiple Sclerosis Data Network. <i>Frontiers in Neurology</i> , 2021, 12, 647811.	2.4	17
45	Real-world disability improvement in patients with relapsing–remitting multiple sclerosis treated with natalizumab in the Tysabri Observational Program. <i>Multiple Sclerosis Journal</i> , 2021, 27, 719-728.	3.0	15
46	Adverse events in second- and third-line treatments for acute and chronic graft-versus-host disease: systematic review. <i>Therapeutic Advances in Hematology</i> , 2020, 11, 204062072097703.	2.5	14
47	Patient-Related Risk Factors for Unplanned 30-Day Hospital Readmission Following Primary and Revision Total Knee Arthroplasty: A Systematic Review and Meta-Analysis. <i>Journal of Clinical Medicine</i> , 2021, 10, 134.	2.4	14
48	What Is the Impact of Advancing Age on the Outcomes of Total Hip Arthroplasty?. <i>Journal of Arthroplasty</i> , 2018, 33, 1101-1107.e1.	3.1	12
49	Risk of requiring a wheelchair in primary progressive multiple sclerosis: Data from the ORATORIO trial and the MSBase registry. <i>European Journal of Neurology</i> , 2022, 29, 1082-1090.	3.3	11
50	Injection drug network characteristics as a predictor of injection behaviour. <i>Epidemiology and Infection</i> , 2019, 147, e173.	2.1	9
51	Long-term outcomes in patients presenting with optic neuritis: Analyses of the MSBase registry. <i>Journal of the Neurological Sciences</i> , 2021, 430, 118067.	0.6	9
52	No evidence for loss of natalizumab effectiveness with every-6-week dosing: a propensity score–matched comparison with every-4-week dosing in patients enrolled in the Tysabri Observational Program (TOP). <i>Therapeutic Advances in Neurological Disorders</i> , 2021, 14, 175628642110424.	3.5	9
53	Assessing the suitability of general practice electronic health records for clinical prediction model development: a data quality assessment. <i>BMC Medical Informatics and Decision Making</i> , 2021, 21, 297.	3.0	9
54	Silent lesions on MRI imaging – Shifting goal posts for treatment decisions in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2018, 24, 1569-1577.	3.0	8

#	ARTICLE	IF	CITATIONS
55	Long-Term Consequences of High Titer Neutralizing Antibodies to Interferon- β in Multiple Sclerosis. <i>Frontiers in Immunology</i> , 2020, 11, 583560.	4.8	8
56	A comparative study of teriflunomide and dimethyl fumarate within the Swedish MS Registry. <i>Multiple Sclerosis Journal</i> , 2022, 28, 237-246.	3.0	8
57	Congenital heart defect repair with ADAPT tissue engineered pericardium scaffold: An early-stage health economic model. <i>PLoS ONE</i> , 2018, 13, e0204643.	2.5	7
58	Multicentre randomised double-blind placebo controlled trial of combination vancomycin and cefazolin surgical antibiotic prophylaxis: the Australian surgical antibiotic prophylaxis (ASAP) trial. <i>BMJ Open</i> , 2019, 9, e033718.	1.9	7
59	Patient-Reported Outcomes Following Total Knee Replacement in Patients \geq 65 Years of Age: A Systematic Review and Meta-Analysis. <i>Journal of Clinical Medicine</i> , 2020, 9, 3150.	2.4	7
60	Clinical outcomes in patients who discontinue natalizumab therapy after 2 years in the Tysabri [®] Observational Program (TOP). <i>Multiple Sclerosis Journal</i> , 2021, 27, 410-419.	3.0	7
61	Women With Chronic Hypoparathyroidism Have Low Risk of Adverse Pregnancy Outcomes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, 3312-3319.	3.6	7
62	The role of Thallium-201 scintigraphy and Tc-99m pentavalent dimercaptosuccinic acid in diagnosis and grading of chondrosarcoma. <i>European Journal of Radiology</i> , 2020, 125, 108846.	2.6	6
63	Subtrochanteric Femur Fractures Treated With Femoral Nail: The Effect of Cerclage Wire Augmentation on Complications, Fracture Union, and Reduction: A Systematic Review and Meta-Analysis of Comparative Studies. <i>Journal of Orthopaedic Trauma</i> , 2022, 36, e142-e151.	1.4	6
64	Patients With High-disease-activity Relapsing-Remitting Multiple Sclerosis in Real-world Clinical Practice: A Population-based Study in Sweden. <i>Clinical Therapeutics</i> , 2020, 42, 240-250.	2.5	5
65	The impact of bariatric surgery on disease activity and progression of multiple sclerosis: A nationwide matched cohort study. <i>Multiple Sclerosis Journal</i> , 2022, 28, 2099-2105.	3.0	5
66	Increased Rate of Hospitalisation for COVID-19 Amongst Rituximab Treated Multiple Sclerosis Patients: A Study of the Swedish MS Registry. <i>SSRN Electronic Journal</i> , 0, , .	0.4	3
67	The Introduction of a Mandatory Mask Policy Was Associated with Significantly Reduced COVID-19 Cases in a Major Metropolitan City. <i>SSRN Electronic Journal</i> , 0, , .	0.4	2
68	A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data. <i>Journal of Visualized Experiments</i> , 2015, , e53169.	0.3	1
69	Real world evidence (RWE) on long-term persistence of fingolimod in relapsing-remitting multiple sclerosis (RRMS) in australia. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2018, 89, A23.3-A24.	1.9	1
70	A Nomogram for Predicting Non-Response to Surgery One Year after Elective Total Hip Replacement. <i>Journal of Clinical Medicine</i> , 2022, 11, 1649.	2.4	1
71	Response to Letter. <i>Journal of Travel Medicine</i> , 2015, 22, 429-430.	3.0	0
72	timing of high-efficacy disease modifying therapies for relapsing-remitting multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2017, 88, e1.11-e1.	1.9	0

#	ARTICLE	IF	CITATIONS
73	Reply to: Comment on Y.D. Fragoso et al.: "Lymphocyte count in peripheral blood is not associated with the level of clinical response to treatment with fingolimod" [Mult. Scler. Relat. Disord. (2017)]. Multiple Sclerosis and Related Disorders, 2018, 22, 166.	2.0	0
74	085...Clinical outcomes were better for relapsing-remitting multiple sclerosis (RRMS) patients who remained on natalizumab compared to those who switched to oral or injectable therapies after 2 years in the tysabri [®] observational program (TOP). Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, A34.2-A34.	1.9	0
75	049...Real world evidence (RWE) on impact of age on long-term persistence to disease modifying therapies (DMTS) in relapsing-remitting multiple sclerosis (RRMS) in australia. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, A16.3-A17.	1.9	0
76	Title is missing!. , 2020, 17, e1003044.		0
77	Title is missing!. , 2020, 17, e1003044.		0
78	Title is missing!. , 2020, 17, e1003044.		0
79	Title is missing!. , 2020, 17, e1003044.		0
80	Title is missing!. , 2020, 17, e1003044.		0
81	023... Relapse outcomes with natalizumab Q4W vs switch to Q6W. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, A20.3-A21.	1.9	0